Canagliflozin
Brand name: Invokana
Rank #215 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$63.7M
Total Cost
66,550
Total Claims
$63.7M
Total Cost
3,505
Prescribers
$956
Cost per Claim
2,006
Beneficiaries
107,093
30-Day Fills
$18K
Avg Cost/Provider
19
Avg Claims/Provider
Share of Medicare Part D Spending
0.02%
of total Medicare Part D spending
$63.7M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $63.7M total
🔎 Data Overview
Average cost of $31,731 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Canagliflozin
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Muhammad Bakleh | Endocrinology | Flint, MI | 147 | $219K |
| 2 | Hasan Qutob | Endocrinology | Jackson, MI | 170 | $202K |
| 3 | Richard Dodd | Endocrinology | Asheville, NC | 170 | $183K |
| 4 | Sharol Patterson | Internal Medicine | Plantation, FL | 169 | $152K |
| 5 | Don Zwickler | Endocrinology | Pomona, NY | 137 | $146K |
| 6 | Wendell Miers | Endocrinology | Lexington, KY | 88 | $127K |
| 7 | Ralph Oiknine | Endocrinology | Chesterfield, MO | 82 | $122K |
| 8 | George Schroeder | Emergency Medicine | Ormond Beach, FL | 162 | $121K |
| 9 | Phong Bui | Internal Medicine | Fountain Valley, CA | 100 | $117K |
| 10 | Rhonda Solomon | Nurse Practitioner | Seneca Falls, NY | 111 | $117K |
| 11 | Annette Kubalek | Nurse Practitioner | Indiana, PA | 122 | $114K |
| 12 | Rodrigo Tobar | Family Practice | Southfield, MI | 73 | $110K |
| 13 | Ahmed Al Jebawi | Endocrinology | Anderson, IN | 77 | $106K |
| 14 | Mark Schutta | Endocrinology | Philadelphia, PA | 61 | $102K |
| 15 | Pritiben Desai | Nurse Practitioner | Wilmington, DE | 51 | $101K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 212 | Netarsudil Mesylate (Rhopressa) | $65.6M | 129,116 |
| 213 | Risperidone Microspheres (Risperdal Consta) | $64.8M | 47,567 |
| 214 | Venlafaxine Hcl (Venlafaxine Hcl) | $64.7M | 2,187,710 |
| 215 | Canagliflozin (Invokana) | $63.7M | 66,550 |
| 216 | Belimumab (Benlysta) | $63.4M | 13,386 |
| 217 | Collagenase Clostridium Hist. (Santyl) | $63.3M | 70,641 |
| 218 | Insulin Lispro Protamin/Lispro (Humalog Mix 75-25 Kwikpen) | $62.8M | 60,873 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology